Norris Medicines Ltd. के निदेशक की रिपोर्ट

Mar 31, 2025

Your Director''s have pleasure in presenting to you their 34th Annual Report on the business and
operations of the Company together with Audited Statement of Accounts for the year ended 31st
March, 2025.

1. FINANCIAL RESULTS:

The Company''s financial performance, for the year ended on 31st March, 2025, is summarized
below:

Particulars	Year ended on	Year ended on
	31st March, 2025	31st March, 2024
	(Rs. in Lacs)	(Rs. in Lacs)
Revenue from Operations	582.02	563.56
Other Income	6.14	2.84
T otal Revenue	588.15	566.40
Profit/(Loss) for the year before Taxes	(117.81)	(109.79)
Less: Provision for Deferred Tax Liabilities/Asset	5.94	8.89
Less: Provision for Income Tax	0.00	0.00
Profit/(Loss) after Taxes	(123.75)	(118.68)
Dividend on Equity Shares	0.00	0.00
Dividend Distribution Tax on Equity Shares	0.00	0.00
Transfer to General Reserve	0.00	0.00
Earning per Equity Shares Basic and Diluted (Rs.)	(1.24)	(1.19)

The income from operations for the FY 2024-2025, was Rs. 588.15 Lakhs as compared with Rs.
566.40 Lakhs during the previous year.

2. STATE OF COMPANY''S AFFAIRS:

Discussion on state of Company''s affairs has been covered as part of the Management Discussion
and Analysis for the year under review.

3. DIVIDEND:

In view of the adverse financial position of the Company and the carried forward losses the
Directors express their inability to declare any dividend for the year. Board of Directors sincerely
hopes that members would appreciate and understand the situation for non-payment of
Dividend.

4. TRANSFER TO RESERVES:

Pursuant to provisions of Section 134(1)(j) of the Companies Act, 2013, in wake of the adverse
financial condition of the Company, the Company has not proposed to transfer any amount to
general reserves account of the company during the year.

5. DETAILS OF SUBSIDIARY, JOINT VENTURE OR ASSOCIATES:

Neither the Company has any Subsidiary, Joint Venture nor Associate Company nor has any other
Company become or ceased to be subsidiary, Joint Venture or Associate Company of the Company.

6. CHANGE IN NATURE OF BUSINESS, IF ANY

Your Company continues to operate in the single business segment as that of previous year and
there is no change in the nature of the business.

7. REPORTING OF FRAUDS

There have been no instances of fraud reported by the statutory auditors under section 143(12) of
the Act and rules framed thereunder either to the Company or to the central government.

8. MANAGEMENT DISCUSSION AND ANALYSIS REPORT

As per the provision of Schedule V of SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015, the Management Discussion and Analysis Report has been included and is
enclosed as (Annexure - B) to this Report.

9. OPERATIONS AND STATE OF AFFAIRS OF THE COMPANY

The turnover including other income of the Company for the Financial Year 2024-25 amounted
to Rs. 588.15 Lakhs as against last year''s Rs. 566.4 Lakhs. The Net Loss is Rs. 125.15 Lakhs as
against Rs. 118.68 Lakhs of last year.

10. CORPORATE GOVERNANCE

In view of Paid up Capital and Net worth of the Company, being lesser then Rs. 10 crores and Rs.
25 crores respectively, Corporate Governance Report as prescribed in clause C of Schedule V to
LODR is not included in terms of Regulation 15(2) of LODR.

11. DIRECTORS

All the Directors of the Company have confirmed that they are not disqualified from being
appointed as Directors in terms of Section 164 of the Companies Act, 2013 and not debarred or
disqualified by the SEBI/ Ministry of Corporate Affairs or any such statutory authority from
being appointed or continuing as Director of the Company or any other Company where such
Director holds such position in terms of Regulation 34(3) and Schedule V Para C clause (10) (i)
of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015) (10)(i) of Part

C of Schedule V of Listing Regulations.

12. KEY MANAGERIAL PERSONNEL

Mr. Vimal D Shah, Director, Mr. Iqubal Patel, Chief Financial Officer and Ms. Priyanka Lohiya,
Company Secretary are Key Managerial Personnel of the Company.

11. INDEPENDENT DIRECTORS

All the Independent Directors have given declarations that they meet the criteria of
independence as laid down under Section 149(6) of the Act read with Regulation 16(1)(b) of
SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''LODR'').

12. PERFORMANCE EVALUATION

Pursuant to the provisions of the Act, and LODR, the Board has carried out an annual
performance evaluation of its own performance, the directors individually as well as the
evaluation of the working of its requisite Committees.

The evaluation has been carried out with a well-structured questionnaire taking into
consideration various aspects and roles of the Board and its Committees.

The Board of Directors expressed its satisfaction with the evaluation process.

13. MEETINGS OF THE BOARD

Six (6) Board Meetings were held during the financial year ended 31st March, 2025. The Board
meetings were held on 29th April, 2024, 29th May, 2024, 14th August, 2024, 25th September,
2024, 14th November, 2024 and 13th February, 2025. The gap between two Board Meeting did
not exceed 120 days. The attendance record of the Directors at the Board Meetings is as under:

Sr. No.	Name of the Director	Designation	No. of Meetings attended/held during tenure
1.	Mr. Vimal D. Shah	Executive Director	6/6
2.	Mr. Shaik Amanullah Mohamed Azmathullah	Non-Executive Independent Director	3/6
3.	Mrs. Susmita Mahapatra	Non-Executive Independent Director	2/6
4.	Mr. Angamuthu Vadivel	Non-Executive Independent Director	5/6
5.	Mr. Praveen J. Bafna	Non-Executive- Non Independent Director	2/6

6.

Ms. Sathya Venkatachalam

Non-Executive Independent Director

1/6

14. AUDIT COMMITTEE:

Four (4) Audit Committee Meetings were held during the financial year ended 31st March,
2025. The Audit Committee meetings were held on 29^th May, 2024, 14^th August, 2024, 14^th
November, 2024 and 13^th February, 2025. Scope of the committee includes matters referred in
section 177 of the Act and regulation 18 read with part C of Schedule II. The Committee inter
alia reviews the Internal Control System, Scope of Internal Audit, Reports of Internal Auditors
and Compliance of various regulations. The Committee reviews the financial statements and
approves the same before they are placed before the Board.

Below given table provides the attendance of the Audit Committee members:

Sr. No.	Name of Members	Position	No. of Meeting Attended
1.	Mr. Angamuthu Vadivel	Chairman	4/4
2.	Mr. Vimal D. Shah	Member	4/4
3.	Mr. Praveen J. Bafna	Member	2/4

It is to be noted that the Committee has been re-constituted accordingly.

15. NOMINATION AND REMUNERATION COMMITTE:

Two (2) Nomination and Remuneration Committee meeting were held during the financial
year ended 31st March, 2025. The Nomination and Remuneration Committee meeting were
held on 29th May, 2024, 14th August, 2024. Scope of the committee includes matters referred
in section 178 of Companies Act, 2013.

Below given table provides the attendance of the Audit Committee members:

Sr. No.	Name of Members	Position	No. of Meeting Attended
1.	Mr. Angamuthu Vadivel	Chairman	2/2
2.	Mr. Praveen J. Bafna	Member	2/2
3.	Ms. Sathya Venkatachalam	Member	1/2

16. STAKEHOLDER RELATIONSHIP COMMITTE:

One (1) Stakeholder Relationship Committee meeting were held during the financial year
ended 31st March, 2024. The Stakeholder Relationship Committee meeting was held on 13th
February, 2025. Scope of the committee includes matters referred in section 178 of Companies
Act, 2013.

Below given table provides the attendance of the Audit Committee members:

Sr. No.	Name of Members	Position	No. of Meeting Attended
1.	Vimal D. Shah	Chairman	1/1
2.	Praveen J. Bafna	Member	1/1
3.	Angamuthu Vadivel	Member	1/1

18. VIGIL MECHANISM / WHISTLE BLOWER POLICY:

The Company has a Whistle Blower Policy pursuant to Section 177 of the Companies Act, 2013
and the rules made thereunder and applicable provisions of the listing agreement and SEBI
(Listing Obligations & Disclosure Requirements) Regulations, 2015, to report genuine
concerns of Directors and Employees. The Policy has been posted on website of the Company,
www.norrispharma.com.

19. INTERNAL CONTROL SYSTEM AND RISK MANAGEMENT POLICY:

The Management has put in place adequate and effective system and manpower for the
purposes of Risk Management. The Company has a system based approach to business risk
management backed by strong internal control systems. In the opinion of the Board, there are
no risks which would threaten the existence of the Company. The Company''s internal control
procedures ensure compliance with various policies, practices and statutes in keeping with
the organization''s pace of growth and increasing complexity of operations. The Company''s
internal auditor team carries out extensive audits throughout the year across all functional
areas, and submits its reports to the Audit Committee of the Board of Directors.

20. CORPORATE SOCIAL RESPONSIBILITY (CSR):

Considering the provisions of the section 135 of the Companies Act, 2013, CSR requirements
are not applicable to your Company.

21. RELATED PARTY TRANSACTION:

There are no material related party transactions which are not in ordinary course of business
or which are not on arm''s length basis and hence there is no information to be provided as
required under Section 134(3)(h) of the Companies Act, 2013 read with Rule 8(2) of the
Companies (Accounts) Rules, 2014. The Board has approved a policy for related party
transactions which has been uploaded on the Company''s website. The web-link as required
under Listing Agreement is as under: https://www.norrispharma.com/investor-
relations.html

22. ENVIRONMENT & SAFETY OF WOMEN AT WORKPLACE:

The Company is conscious of the importance of environmentally clean and safe operations.
The Company''s policy requires conduct of operations in such a manner so as to ensure safety
of all concerned compliances environmental requirement regulations and preservation of
natural resources. As required by the Sexual Harassment of Women at Workplace
(Prevention, Prohibition and Redressal) Act, 2013, the Company has formulated and
implemented a policy on prevention of sexual harassment at workplace with a mechanism of
lodging complaints. All employees (permanent, contractual, temporary, trainees) are covered
under this policy. During the year under review, no complaints were reported to the Board.

Your Directors further state that during the F.Y. 2024-25, there were no complaints received
pursuant to the POSH Act. The following is reported pursuant to Section 22 of the POSH Act:

a) Number of complaints filed during the F.Y.: Nil

b) Number of complaints disposed off during the F.Y.: Nil

c) Number of complaints pending as on end of the F.Y.: Nil

23. PUBLIC DEPOSITS

During the year under the review, the Company has not invited/accepted any deposits from
public.

24. LOANS, GUARANTEES OR INVESTMENTS

The Company has not given loans and advances of Rs. 1,99,035/- as against previous year of
Rs. 1,35,198/-, under section 186 to any person or body corporate.

25. LISTING OF SHARES AND SHARE CAPITAL

The Equity Shares of the Company are listed on BSE Limited (BSE) with scrip code number
524414. The Annual Listing Fees for the financial year 2025-26 has not been paid to the Stock
Exchange. During the year under review, there was no change in share capital.

26. AUDITORS

(a) STATUTORY AUDITORS:

M/s. BAHEDIA & ASSOCIATES, Chartered Accountants (Firm Registration no.
114421W) were appointed as the Statutory Auditors of the Company to hold office for
five consecutive years starting from the conclusion of the 32nd Annual General Meeting
(AGM) held on 23rd September, 2023 until the conclusion of the 37th AGM of the
Company to be held in the year 2028. The term of office of M/s BAHEDIA & ASSOCIATES,
as Statutory Auditors of the Company will conclude from the close of the forthcoming AGM
of the Company.

During the year Company has not maintained Audit Trail and is in the process of rectifying
the same.

(b) SECRETARIAL AUDITORS:

The Board of Directors of the Company appointed HSPN ASSOCIATES AND LLP,
Practicing Company Secretary, Mumbai as Secretarial Auditor for undertaking
Secretarial Audit of the Company for the financial year 2024-25.

The Secretarial Audit Report of HSPN ASSOCIATES AND LLP, Practicing Company
Secretary for the financial year ended 31st March, 2025 is annexed as (Annexure - E). The
Secretarial Audit Report does contain qualification, reservation or adverse remark
regarding non-compliances related to FY 2024-2025. Board would like to bring to
members attention that due to resignation of Company Secretary and change in internal
as well as external Compliance team members there was gap in meeting the Compliance
requirements for FY 2023-2024. However, the same will be rectified and corrected now
onwards.

(C) INTERNAL AUDITORS:

The Board of Directors has appointed M/s. Dhiren Y Parikh & Co., Chartered

Accountants as Internal Auditors of the Company for the financial year 2025-26.

27. PARTICULARS OF EMPLOYEES AND RELATED DISCLOSURES:

The information required under Section 197 of the Companies Act, 2013 read with Rule 5(1)
of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, is
annexed herewith (Annexure C).

28. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE
EARNING AND OUTGO:

The details of conservation of energy, technology absorption, foreign exchange earnings and
outgo are attached herewith. (Annexure - D)

29. EXTRACT OF THE ANNUAL RETURN:

The extract of Annual Return pursuant to Section 92(3), 134 and any other provisions
applicable if any of the Act, read with Rule 12(1) of the Companies (Management and
Administration) Rules, 2014 is available on web link
http://norrispharma.com/notice/announcements/.

30. MATERIAL CHANGES:

There have been no material changes and commitments affecting the financial position of the
Company since the close of financial year i.e. since 31st March, 2025. Further, it is hereby
confirmed that Company has received application for Reclassification of Promoter and has
filed an application with BSE dated 18th February, 2025. The Company has filed an appeal
against the said order dated 14.11.2019 before the High Court of Mumbai & obtained stay.
Under Criminal Appeal no. 89 of 2020. No hearing of the Case come up before High court
during the year under review. The Company us also protected by BIFR under case
No.90/2004.

31. DETAILS OF DIRECTORS AND KEY MANAGERIAL PERSONNEL:

The Company has a professional Board with Executive Directors & Non-Executive Directors who
bring the right mix of knowledge, skills, and expertise and help the Company in implementing the
best Corporate Governance practices. Mr. Praveen J. Bafna, Directors of the Company will retire
by rotation at this 34th Annual General Meeting and being eligible offered him/ themselves for re¬
appointment as per Section 152 of the Companies Act, 2013.

During the year under review Mr. Anagamuthu Vadivel was appointed as an Independent Director
of the Company with effect from 29^th April, 2024 and his/her appointment was approved by the
Members in the 33rd Annual General Meeting held on 30^th September, 2024.

During the year under review Mr. Praveen J. Bafna was appointed as a Non- Executive Non¬
Independent Director of the Company with effect from 24^th August, 2024 and his appointment
was approved by the Members in the 33rd Annual General Meeting held on 30^th September, 2024.
During the year under review Ms. Sathya Venkatachalam was appointed as an Independent
Director of the Company with effect from 25^th September, 2024 and her appointment is to be
approved by members in this ensuing AGM to be held on 29th September, 2025.

During the year under review Ms. Priyanka Lohiya was appointed as Company Secretary of the
Company w.e.f. 03^rd July, 2024.

32. DIRECTORS'' RESPONSIBILITY STATEMENT

The Directors'' Responsibility Statement referred to in clause (c) of sub-section (3) of Section
134 of the Companies Act, 2013, shall state that—

a) in the preparation of the annual accounts, the applicable accounting standards had been
followed along with proper explanation relating to material departures;

b) the directors had selected such accounting policies and applied them consistently and made
judgments and estimates that are reasonable and prudent so as to give a true and fair view of
the state of affairs of the company at the end of the financial year and of the loss of the company
for that period;

c) the directors had taken proper and sufficient care for the maintenance of adequate
accounting records in accordance with the provisions of this Act for safeguarding the assets of
the company and for preventing and detecting fraud and other irregularities;

d) the directors had prepared the annual accounts on a going concern basis; and

e) the directors had laid down internal financial controls to be followed by the company and
that such internal financial controls are adequate and were operating effectively.

f) the directors had devised proper systems to ensure compliance with the provisions of all
applicable laws and that such systems were adequate and operating effectively.

32. INSURANCE:

All the properties and insurable interests of the Company including buildings, plant and
machineries and stocks have been adequately insured.

33. FRAUD REPORTING:

During the Financial Year under review, the Statutory Auditors have not reported any incident
of fraud to the Board of Directors of the Company, pursuant to the provisions of Section
143(12) of the Companies Act, 2013.

34. DETAILS OF APPLICATION MADE OR ANY PROCEEDING PENDING UNDER THE
INSOLVENCY AND BANKRUPTCY CODE, 2016 DURING THE YEAR ALONG WITH THEIR
STATUS AS AT THE END OF THE FINANCIAL YEAR:

During the Financial Year 2024-2025, there was no application made and proceeding initiated
/ pending under the Insolvency and Bankruptcy Code, 2016, by any Financial and/or
Operational Creditors against your Company.

As on the date of this Report, there is no application or proceeding pending against your
Company under the Insolvency and Bankruptcy Code, 2016.

35. DETAILS OF DIFFERENCE BETWEEN AMOUNT OF THE VALUATION DONE AT THE TIME
OF ONE TIME SETTLEMENT AND THE VALUATION DONE WHILE TAKING LOAN FROM THE
BANKS OR FINANCIAL INSTITUTIONS ALONG WITH THE REASONS THEREOF:

During the Financial Year 2024-2025, the Company has not made any settlement with its
bankers from which it has accepted any term loan.

36. STATEMENT ON COMPLIANCE WITH THE MATERNITY BENEFIT ACT, 1961

The Company continues to comply with the provisions of the Maternity Benefit Act, 1961,
as amended. Adequate measures have been taken to ensure that all eligible women employees
are granted maternity benefits in accordance with the applicable legal provisions.

The Company provides paid maternity leave, nursing breaks, and ensures a safe and
supportive work environment for women employees returning to work post-maternity. In
addition, the Company complies with the provision of creche facilities as required under the
Maternity Benefit (Amendment) Act, 2017, where applicable.

The Board remains committed to upholding employee welfare and promoting gender-
inclusive workplace policies.

36. OTHER DISCLOSURES

There were no transactions on the following matters during the year under review and hence
no reporting or disclosure is required:

• Issue of equity shares with differential rights as to dividend, voting or otherwise.

• Issue of shares (including sweat equity shares) to employees of the Company under any
scheme.

• There is no proceeding pending under the Insolvency and Bankruptcy Code, 2016.

• There was no instance of one-time settlement with any Bank or Financial Institution.

36. INTERNAL FINANCIAL CONTROLS

The Company has adequate system of internal controls to safeguard and protect from loss,
unauthorized use or disposition of its assets commensurate with its size, scale and
complexities of its operations. The internal auditor of the Company checks and verifies the
internal control and monitors them. The Audit Committee of the Company actively reviews
the adequacy and effectiveness of the internal control systems and suggests improvements to
strengthen the same. All the transactions are properly authorized, recorded and reported to
the Management. The Company is following all the applicable accounting standards for
properly maintaining the books of accounts and reporting financial statements.

36. ACKNOWLEDGEMENTS

The Board of Directors gratefully acknowledges the assistance and co-operation received
from the Bankers all other statutory and non-statutory agencies for their co-operation. The
Board of Directors also wish to place on record their gratitude and appreciation to the
members for their trust and confidence shown in the Company. The Board of Directors would
like to especially thank all the employees of the Company for their dedication and loyalty.

Date: 01^st September, 2025
By Order of the Board

Registered Office: For Norris Medicines Limited

Plot No. 801/P,

GIDC Industrial Estate,

Ankleshwar-393 002 (Gujarat) SD/-

CIN: L24230GJ1990PLC086581 Vimal D. Shah

Email: [email protected] Director

DIN No. 01506655

---

Mar 31, 2024

Your Director''s have pleasure in presenting to you their 33rd Annual Report on the business and
operations of the Company together with Audited Statement of Accounts for the year ended 31st
March, 2024.

FINANCIAL RESULTS:

The Company''s financial performance, for the year ended on 31st March, 2023, is summarized
below:

Particulars	Year ended on	Year ended on
	31st March, 2024	31st March, 2023
	(Rs. in Lacs)	(Rs. in Lacs)
Revenue from Operations	563.56	835.82
Other Income	2.84	1.45
Total Revenue	566.40	837.27
Profit/(Loss] for the year before Taxes	(109.79]	(119.33]
Less: Provision for Deferred Tax Liabilities/Asset	88.89	55.62
Less: Provision for Income Tax	0.00	0.00
Profit/(Loss] after Taxes	(118.68]	(174.95]
Dividend on Equity Shares	0.00	0.00
Dividend Distribution Tax on Equity Shares	0.00	0.00
Transfer to General Reserve	0.00	0.00
Earning per Equity Shares Basic and Diluted (Rs.]	(1.19]	(1.75]

The income from operations for the FY 2023-2024, was Rs. 563.56 Lakhs as compared with Rs.
835.82 Lakhs during the previous year.

1. DIVIDEND:

In view of the adverse financial position of the Company and the carried forward losses the
Directors express their inability to declare any dividend for the year. Board of Directors
sincerely hopes that members would appreciate and understand the situation for non-payment
of Dividend.

2. TRANSFER TO RESERVES:

Pursuant to provisions of Section 134(1)(j) of the Companies Act, 2013, the company has not
proposed to transfer any amount to general reserves account of the company during the year.

3. DETAILS OF SUBSIDIARY, JOINT VENTURE OR ASSOCIATES:

Neither the Company has any Subsidiary, Joint Venture nor Associate Company nor has any other

Company become or ceased to be subsidiary, Joint Venture or Associate Company of the
Company.

4. CHANGE IN NATURE OF BUSINESS, IF ANY

Your Company continues to operate in the single business segment as that of previous year and
there is no change in the nature of the business.

5. REPORTING OF FRAUDS

There have been no instances of fraud reported by the statutory auditors under section 143(12) of
the Act and rules framed thereunder either to the Company or to the central government.

6. MANAGEMENT DISCUSSION AND ANALYSIS REPORT

As per the provision of Schedule V of SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015, the Management Discussion and Analysis Report has been included and is
enclosed as (Annexure - B) to this Report.

7. OPERATIONS AND STATE OF AFFAIRS OF THE COMPANY

The turnover including other income of the Company for the Financial Year 2023-24
amounted to Rs. 566.4 Lakhs as against last year''s Rs. 837.27 Lakhs. The Net Loss is Rs. 118.68
Lakhs as against Rs. 174.95 Lakhs of last year.

8. CORPORATE GOVERNANCE

In view of Paid up Capital and Net worth of the Company, being lesser then Rs. 10 crores and
Rs. 25 crores respectively, Corporate Governance Report as prescribed in clause C of Schedule
V to LODR is not included in terms of Regulation 15(2) of LODR.

9. DIRECTORS

All the Directors of the Company have confirmed that they are not disqualified from being
appointed as D irectors in terms of Section 164 of the Companies Act, 2013 and not debarred or
disqualified by the SEBI/ Ministry of Corporate Affairs or any such statutory authority from
being appointed or continuing as Director of the Company or any other Company where such
Director holds such position in terms of Regulation 34(3) and Schedule V Para C clause (10) (i)
of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015) (10)(i) of
Part C of Schedule V of Listing Regulations.

10. KEY MANAGERIAL PERSONNEL

Mr. Vimal D Shah, Managing Director, Mr. Angamuthu Vadivel, Independent Director, Mr.
Praveen J. Bafna, Non-Executive Director, Mr. Iqbal Patel, Chief Financial Officer and CS Ms.
Prerna Karwa, Company Secretary (resigned w.e.f. 29^th March, 2024), Mr. Hiten Parikh,
Independent Director (Resigned w.e.f. 29^th March, 2024) and Susmita Mahapatra, Director are
Key Managerial Personnel of the Company.

11. INDEPENDENT DIRECTORS

All the Independent Directors have given declarations that they meet the criteria of
independence as laid down under Section 149(6) of the Act read with Regulation 16(1)(b) of
SEBI (Listing Obligations and Disclosure Requirements] Regulations, 2015 (''LODR''].

12. PERFORMANCE EVALUATION

Pursuant to the provisions of the Act, and LODR, the Board has carried out an annual
performance evaluation of its own performance, the directors individually as well as the
evaluation of the working of its requisite Committees.

The evaluation has been carried out with a well-structured questionnaire taking into
consideration various aspects and roles of the Board and its Committees.

The Board of Directors expressed its satisfaction with the evaluation process.

13. MEETINGS OF THE BOARD

Seven (7) Board Meetings were held during the financial year ended 31st March, 2024. The
Board meetings were held on 25th May, 2023, 10th August, 2023, 1st September, 2023, 10th
November, 2023 and 18^th November, 2023, 29th December, 2023, and 14th February, 2024.
The gap between two Board Meeting did not exceed 120 days. The attendance record of the
Directors at the Board Meetings is as under: -

Sr. No.	Name of the Director	Designation	No. of Meetings attended/held during tenure
1.	Mr. Vimal D. Shah	Executive Director	7/7
2.	Dr. Hiten M. Parikh	Non-Executive Independent Director	7/7
3.	Mr. Shaik Amanullah Mohamed Azmathullah	Non-Executive Independent Director	7/7
4.	Mrs. Susmita Mahapatra	Non-Executive Independent Director	7/7

14. AUDIT COMMITTEE:

Four (4) Audit Committee Meetings were held during the financial year ended 31st March,
2024. The Audit Committee meetings were held on 25th May, 2023, 10th August, 2023, 10th
November, 2023 and 14th February, 2024. Scope of the committee includes matters referred
in section 177 of the Act and regulation 18 read with part C of Schedule II. The Committee
inter alia reviews the Internal Control System, Scope of Internal Audit, Reports of Internal
Auditors and Compliance of various regulations. The Committee reviews the financial
statements and approves the same before they are placed before the Board.

Below given table provides the attendance of the Audit Committee members:

Sr. No.	Name of Members	Position	No. of Meeting Attended
1.	Dr. Hiten M. Parikh	Chairman	4/4
2.	Mr.Shaik Amanullah Mohamed Azmathullah	Member	4/4
3.	Mr. Vimal D. Shah	Member	4/4

15. NOMINATION AND REMUNERATION COMMITTE:

One (4] Nomination and Remuneration Committee meeting were held during the financial
year ended 31st March, 2024. The Nomination and Remuneration Committee meeting were
held on 25th May, 2023, 10th August, 2023, 10th November, 2023 and 14^th February, 2024.
Scope of the committee includes matters referred in section 178 of Companies Act, 2013.

Below given table provides the attendance of the Audit Committee members:

Sr. No.	Name of Members	Position	No. of Meeting Attended
1.	Ms. Susmita Maapatra	Chairman	4/4
2.	Dr. Hiten M. Parikh	Member	4/4
3.	Mr.Shaik Amanullah Mohamed Azmathullah	Member	4/4

16. STAKEHOLDER RELATIONSHIP COMMITTE:

One (4) Stakeholder Relationship Committee meeting were held during the financial year
ended 31st March, 2024. The Nomination and Remuneration Committee meeting were held
on 25th May, 2023, 10th August, 2023, 10th November, 2023 and 14^th February, 2024.
Scope of the committee includes matters referred in section 178 of Companies Act, 2013.

Below given table provides the attendance of the Audit Committee members:

Sr. No.	Name of Members	Position	No. of Meeting Attended
1.	Dr. Hiten M. Parikh	Chairman	4/4
2.	Mr.Shaik Amanullah Mohamed Azmathullah	Member	4/4
3.	Mr. Vimal D. Shah	Member	4/4

18. VIGIL MECHANISM / WHISTLE BLOWER POLICY:

The Company has a Whistle Blower Policy pursuant to Section 177 of the Companies Act,
2013 and the rules made thereunder and applicable provisions of the listing agreement and
SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, to report genuine
concerns of Directors and Employees. The Policy has been posted on website of the
Company, www.norrispharma.com.

19. INTERNAL CONTROL SYSTEM AND RISK MANAGEMENT POLICY:

The Management has put in place adequate and effective system and manpower for the
purposes of Risk Management. The Company has a system based approach to business risk
management backed by strong internal control systems. In the opinion of the Board, there
are no risks which would threaten the existence of the Company. The Company''s internal
control procedures ensure compliance with various policies, practices and statutes in
keeping with the organization''s pace of growth and increasing complexity of operations. The
Company''s internal auditor team carries out extensive audits throughout the year across all
functional areas, and submits its reports to the Audit Committee of the Board of Directors.

20. CORPORATE SOCIAL RESPONSIBILITY (CSR):

Considering the provisions of the section 135 of the Companies Act, 2013, CSR requirements
are not applicable to your Company.

21. RELATED PARTY TRANSACTION:

There are no material related party transactions which are not in ordinary course of
business or which are not on arm''s length basis and hence there is no information to be
provided as required under Section 134(3)(h) of the Companies Act, 2013 read with Rule
8(2) of the Companies (Accounts) Rules, 2014. The Board has approved a policy for related
party transactions which has been uploaded on the Company''s website. The web-link as
required under Listing Agreement is as under: https://www.norrispharma.com/investor-
relations.html

22. ENVIRONMENT & SAFETY OF WOMEN AT WORKPLACE:

The Company is conscious of the importance of environmentally clean and safe operations.
The Company''s policy requires conduct of operations in such a manner so as to ensure safety
of all concerned compliances environmental requirement regulations and preservation of
natural resources. As required by the Sexual Harassment of Women at Workplace
(Prevention, Prohibition and Redressal) Act, 2013, the Company has formulated and
implemented a policy on prevention of sexual harassment at workplace with a mechanism
of lodging complaints. All employees (permanent, contractual, temporary, trainees) are
covered under this policy. During the year under review, no complaints were reported to
the Board.

The summary of sexual harassment complaints received and disposed off during the
financial year 2023 - 2024 is as under: -

• Number of Complaints Received: Nil

• Number of Complaints Disposed off: Nil

23. DEPOSITS

During the year under the review, the Company has not invited/accepted any deposits from
public.

24. LOANS, GUARANTEES OR INVESTMENTS

The Company has not given any loan, guarantees or investments under section 186 to any
person or body corporate.

25. LISTING OF SHARES AND SHARE CAPITAL

The Equity Shares of the Company are listed on BSE Limited (BSE) with scrip code number
524414. The Annual Listing Fees for the financial year 2023-24 has been paid to the Stock
Exchange. During the year under review, there was no change in share capital.

26. AUDITORS

(a) STATUTORY AUDITORS: M/s. BAHEDIA & ASSOCIATES, Chartered Accountants (Firm
Registration no. 114421W) were appointed as the Statutory Auditors of the Company to
hold office for five consecutive years starting from the conclusion of the 32nd Annual
General Meeting (AGM) held on 23rd September, 2023 until the conclusion of the 37th AGM
of the Company to be held in the year 2028. The term of office of M/s BAHEDIA &
ASSOCIATES, as Statutory Auditors of the Company will conclude from the close of the
forthcoming AGM of the Company.

The Auditors'' Report is unmodified i.e. it does not contain any qualification, reservation or
adverse remark or disclaimer.

(b) SECRETARIAL AUDITORS: The Board of Directors of the Company appointed HSPN
ASSOCIATES AND LLP, Practicing Company Secretary, Mumbai as Secretarial Auditor for
undertaking Secretarial Audit of the Company for the financial year 2023-24. Previously
Payal Tachak and Associates, Practicing Company Secretary, Mumbai were acting as
Secretarial Auditors for undertaking Secretarial Audit of the Company for the financial year

2022- 23.

The Secretarial Audit Report of HSPN ASSOCIATES AND LLP, Practicing Company Secretary
for the financial year ended 31st March, 2024 is annexed as (Annexure - E). The Secretarial
Audit Report does contain qualification, reservation or adverse remark regarding Non¬
compliances related to FY 2023-2024. Board would like to bring to members attention that
due to resignation of Company Secretary and change in internal as well as external
Compliance team members there was gap in meeting the Compliance requirements for FY

2023- 2024. However, the same will be rectified and corrected now onwards.

(c) INTERNAL AUDITORS: The Board of Directors has appointed M/s. Dhiren Y Parikh & Co.,
Chartered Accountants as Internal Auditors of the Company for the financial year 2023-24.

27. PARTICULARS OF EMPLOYEES AND RELATED DISCLOSURES:

The information required under Section 197 of the Companies Act, 2013 read with Rule 5(1)
of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, is
annexed herewith (Annexure C).

28. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE
EARNING AND OUTGO:

The details of conservation of energy, technology absorption, foreign exchange earnings and
outgo are attached herewith. (Annexure - D)

29. EXTRACT OF THE ANNUAL RETURN:

The extract of Annual Return pursuant to Section 92(3), 134 and any other provisions
applicable if any of the Act, read with Rule 12(1) of the Companies (Management and
Administration) Rules, 2014 is available on web link
http://norrispharma.com/notice/announcements/.

30. MATERIAL CHANGES:

There have been no material changes and commitments affecting the financial position of the
Company since the close of financial year i.e. since 31st March, 2023. Further, it is hereby
confirmed that there has been no change in the nature of business of the Company.

31. DIRECTORS'' RESPONSIBILITY STATEMENT

The Directors'' Responsibility Statement referred to in clause (c] of sub-section (3) of Section
134 of the Companies Act, 2013, shall state that—

a) in the preparation of the annual accounts, the applicable accounting standards had been
followed along with proper explanation relating to material departures;

b) the directors had selected such accounting policies and applied them consistently and
made judgments and estimates that are reasonable and prudent so as to give a true and fair
view of the state of affairs of the company at the end of the financial year and of the loss of
the company for that period;

c) the directors had taken proper and sufficient care for the maintenance of adequate
accounting records in accordance with the provisions of this Act for safeguarding the assets
of the company and for preventing and detecting fraud and other irregularities;

d) the directors had prepared the annual accounts on a going concern basis; and

e) the directors had laid down internal financial controls to be followed by the company and
that such internal financial controls are adequate and were operating effectively.

f) the directors had devised proper systems to ensure compliance with the provisions of all
applicable laws and that such systems were adequate and operating effectively.

32. INSURANCE:

All the properties and insurable interests of the Company including buildings, plant and
machineries and stocks have been adequately insured.

33. FRAUD REPORTING:

During the Financial Year under review, the Statutory Auditors have not reported any
incident of fraud to the Board of Directors of the Company, pursuant to the provisions of
Section 143(12) of the Companies Act, 2013.

34. DETAILS OF APPLICATION MADE OR ANY PROCEEDING PENDING UNDER THE
INSOLVENCY AND BANKRUPTCY CODE, 2016 DURING THE YEAR ALONG WITH THEIR
STATUS AS AT THE END OF THE FINANCIAL YEAR:

During the Financial Year 2023-2024, there was no application made and proceeding initiated
/ pending under the Insolvency and Bankruptcy Code, 2016, by any Financial and/or
Operational Creditors against your Company.

As on the date of this Report, there is no application or proceeding pending against your
Company under the Insolvency and Bankruptcy Code, 2016.

35. DETAILS OF DIFFERENCE BETWEEN AMOUNT OF THE VALUATION DONE AT THE TIME
OF ONE TIME SETTLEMENT AND THE VALUATION DONE WHILE TAKING LOAN FROM
THE BANKS OR FINANCIAL INSTITUTIONS ALONG WITH THE REASONS THEREOF:

During the Financial Year 2023-2024, the Company has not made any settlement with its
bankers from which it has accepted any term loan.

36. ACKNOWLEDGEMENTS

The Board of Directors gratefully acknowledges the assistance and co-operation received from
the Bankers all other statutory and non-statutory agencies for their co-operation. The Board of
Directors also wish to place on record their gratitude and appreciation to the members for their
trust and confidence shown in the Company. The Board of Directors would like to especially
thank all the employees of the Company for their dedication and loyalty.

Date: 14^th August, 2024

By Order of the Board

Registered Office: For Norris Medicines Limited

Plot No. 801/P,

GIDC Industrial Estate,

Ankleshwar-393 002 (Gujarat) SD/-

CIN : L24230GJ1990PLC086581 Vimal D. Shah

Email: [email protected] Managing Director

DIN No. 01506655

---

Mar 31, 2023

BOARD''S REPORT

To,

The Members,

Your Directors have pleasure in presenting their 32st Annual Report on the business and operations of the
Companytogether with Audited Statement of Accounts for the year ended 31^st March, 2023.

1. FINANCIAL RESULTS:

The Company''s financial performance, for the year ended on 31^st March, 2023, is summarized below:

Particulars	Year ended on 31st March, 2023	Year ended on 31st March, 2022
Revenue from Operations	835.82	943.84
Other Income	1.45	2.58
Total Revenue	837.27	946.42
Profit/ (Loss) for the year before Taxes	(119.33)	(218.45)
Less: Provision for Deferred Tax Liabilities/Asset	55.62	107.90
Less: Provision for Income Tax	0.00	0.00
Profit/(Loss) after Taxes	(174.95)	(326.35)
Dividend on Equity Shares	0.00	0.00
Dividend Distribution Tax on Equity Shares	0.00	0.00
Transfer to General Reserve	0.00	0.00
Earning per Equity Shares Basic and Diluted (Rs.)	(1.75)	(3.26)

The income from operations for the FY 2022-2023, was Rs. 835.82 Lakhs as compared with Rs. 943.84
Lakhs during the previous year.

2. DIVIDEND:

In view of the adverse financial position of the Company and the carried forward losses the Directors
express their inability to declare any dividend for the year. Board of Directors sincerely hopes that
members would appreciate and understand the situation for non-payment of Dividend.

3. TRANSFER TO RESERVES:

Pursuant to provisions of Section 134(1)(j) of the Companies Act, 2013, the company has not
proposed totransfer any amount to general reserves account of the company during the year.

4. DETAILS OF SUBSIDIARY, JOINT VENTURE OR ASSOCIATES:

Neither the Company has any Subsidiary, Joint Venture nor Associate Company nor has any other Company
become or ceased to be subsidiary, Joint Venture or Associate Company of the Company.

5. CHANGE IN NATURE OF BUSINESS, IF ANY

Your Company continues to operate in the single business segment as that of previous year and there
is nochange in the nature of the business.

6. REPORTING OF FRAUDS

There have been no instances of fraud reported by the statutory auditors under section 143(12) of the Act
andrules framed thereunder either to the Company or to the central government.

7. MANAGEMENT DISCUSSION AND ANALYSIS REPORT

As per the provision of Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations,
2015, the Management Discussion and Analysis Report has been included and is enclosed as (Annexure -
B) to this Report.

8. OPERATIONS AND STATE OF AFFAIRS OF THE COMPANY

The turnover including other income of the Company for the Financial Year 2022-23 amounted to
Rs.837.26.Lakhs as against last year''s Rs. 946.42Lakhs. The Net Loss is Rs.174.95 Lakhs as against Rs.
326.35 Lakhs of last year.

9. CORPORATE GOVERNANCE

In view of Paid up Capital and Net worth of the Company, being lesser then Rs. 10 crores and Rs. 25 crores
respectively, Corporate Governance Report as prescribed in clause C of Schedule V to LODR is not included
in terms of Regulation 15(2) of LODR.

10. DIRECTORS

All the Directors of the Company have confirmed that they are not disqualified from being appointed as
Directors in terms of Section 164 of the Companies Act, 2013 and not debarred or disqualified by the SEBI
/ Ministry of Corporate Affairs or any such statutory authority from being appointed or continuing as
Director of the Company or any other Company where such Director holds such position in terms of
Regulation 34(3) and Schedule V Para C clause (10)(i) of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015) (10)(i) of Part C of Schedule V of Listing Regulations

11. KEY MANAGERIAL PERSONNEL

Mr. Vimal D Shah, Managing Director, Mr. Iqubal Patel, Chief Financial Officer and CS Ms. Prena Karwa,
Company Secretary are Key Managerial Personnel of the Company.

12. INDEPENDENT DIRECTORS

All the Independent Directors have given declarations that they meet the criteria of independence as laid
down under Section 149(6) of the Act read with Regulation 16(1)(b) of SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015 (''LODR'')

13. PERFORMANCE EVALUATION

Pursuant to the provisions of the Act, and LODR, the Board has carried out an annual performance
evaluation of its own performance, the directors individually as well as the evaluation of the working of its
requisite Committees.

The evaluation has been carried out with a well-structured questionnaire taking into consideration various
aspects and roles of the Board and its Committees.

The Board of Directors expressed its satisfaction with the evaluation process.

14. MEETINGS OF THE BOARD

Six (6) Board Meetings were held during the financial year ended 31^st March, 2023. The Board meetings
were held on 25^th May, 2022, 31^st August, 2022, 1^st October, 2022, 7^th November, 2023 and 13^{th February},
2023. The gap between two Board Meeting did not exceeded 120 days. The attendance record of the
Directors at the Board Meetings is as under:-

Sr. No.	Name of the Director	Designation	No. of Meetings attended/held during tenure
1	Mr. Vimal D. Shah	Executive Director	6/6
2	Dr. Hiten M. Parikh	Non Executive Independent Director	6/6
3	Mr. Shaik Amanullah Mohamed Azmathullah	Non Executive Independent Director	6/6
4.	Mrs. Susmita Mahapatra	Non Executive Independent Director	6/6

15. AUDIT COMMITTEE:

Four (4) Audit Committee Meetings were held during the financial year ended 31^st March, 2023. The Audit
Committee meetings were held on 25^th May, 2022, 31^st August, 2022, 7^th November, 2022 and 13^th
February, 2023. Scope of the committee includes matters referred in section 177 of the Act and regulation
18 read with part C of Schedule II. The Committee inter alia reviews the Internal Control System, Scope of
Internal Audit, Reports of Internal Auditors and Compliance of various regulations. The Committee reviews
the financial statements and approves the same before they are placed before the Board.

Below given table provides the attendance of the Audit Committee members:

Sr. No.	Name of the Member	Position	No. of Meetings attended / held during tenure
1.	Dr. Hiten M. Parikh	Chairman	4/4
2.	Mr.Shaik Amanullah Mohamed Azmathullah	Member	4/4
3	Mr. Vimal D. Shah	Member	4/4

16. NOMINATION AND REMUNERATION COMMITTEE:

The Nomination and Remuneration Committee met once during the year under review on 7^{th November},
²⁰²². Below given table provides the attendance of the Nomination and Remuneration Committee
members:

Sr. No.	Name of the Member	Position	No. of Meetings attended/held
			during tenure
1	Mrs. Susmita Mahapatra	Chairman	1/1
2	Dr. Hiten M. Parikh	Member	1/1
3	Mr. Shaik Amanullah Mohamed Azmathullah	Member	1/1

17. STAKEHOLDERS RELATIONSHIP COMMITTEE:

The Stakeholders Relationship Committee met twice during the year under review on 7^th November, 2022
and 13^th February 2023.

Below given table provides the attendance of the Stakeholders Relationship Committee members:

Sr. No.	Name of the Member	Position	No. of Meetings attended/held
			during tenure
1	Dr. Hiten Parikh	Chairman	2/2
2	Mr. Vimal D. Shah	Member	2/2
3	Mr. Shaik Amanullah Mohamed Azmathullah	Member	2/2

18. VIGIL MECHANISM / WHISTLE BLOWER POLICY:

The Company has a Whistle Blower Policy pursuant to Section 177 of the Companies Act, 2013 and the
rules made thereunder and applicable provisions of the listing agreement and SEBI (Listing Obligations &
Disclosure Requirements) Regulations, 2015, to report genuine concerns of Directors and Employees. The
Policy has been posted on website of the Company, www.norrispharma.com

19. INTERNAL CONTROL SYSTEM AND RISK MANAGEMENT POLICY:

The Management has put in place adequate and effective system and manpower for the purposes of Risk
Management. The Company has a system based approach to business risk management backed by strong
internal control systems. In the opinion of the Board, there are no risks which would threaten the existence
of the Company

The Company''s internal control procedures ensure compliance with various policies, practices and statutes
in keeping with the organization''s pace of growth and increasing complexity of operations. The Company''s
internal auditor team carries out extensive audits throughout the year across all functional areas, and
submits its reportsto the Audit Committee of the Board of Directors.

20. CORPORATE SOCIAL RESPONSIBILITY (CSR):

Considering the provisions of the section 135 of the Companies Act, 2013, CSR requirements are not
applicable to your Company.

21. RELATED PARTY TRANSACTION:

There are no material related party transactions which are not in ordinary course of business or which are
not on arm''s length basis and hence there is no information to be provided as required under Section
134(3)(h) of the Companies Act, 2013 read with Rule 8(2) of the Companies (Accounts) Rules, 2014.

The Board has approved a policy for related party transactions which has been uploaded on the Company''s
website. The web-link as required under Listing Agreement is as under:
https://www.norrispharma.com/investor- relations.html

22. ENVIRONMENT & SAFETY OF WOMEN AT WORKPLACE:

The Company is conscious of the importance of environmentally clean and safe operations. The Company''s
policy requires conduct of operations in such a manner so as to ensure safety of all concerned compliances
environmental requirement regulations and preservation of natural resources.

As required by the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal)
Act, 2013, the Company has formulated and implemented a policy on prevention of sexual harassment at
workplace with a mechanism of lodging complaints. All employees (permanent, contractual, temporary,
trainees) are covered under this policy. During the year under review, no complaints were reported to the
Board.

The summary of sexual harassment complaints received and disposed off during the financial year
2022 - 23 is as under:

- Number of Complaints Received : Nil

- Number of Complaints Disposed off : Nil

23. DEPOSITS

During the year under the review, the Company has not invited/accepted any deposits from public.

24. LOANS, GUARANTEES OR INVESTMENTS

The Company has not given any loan, guarantees or investments under section 186 to any person or body
corporate.

25. LISTING OF SHARES AND SHARE CAPITAL

The Equity Shares of the Company are listed on BSE Limited (BSE) with scrip code number 524414. The
Annual Listing Fees for the financial year 2022-23 has been paid to the Stock Exchange. During the year
under review, there was no change in share capital.

26. AUDITORS(a) STATUTORY AUDITORS:

M/s. BAHEDIA & ASSOCIATES, Chartered Accountants (Firm Registration no. 114421W) were
appointed as the Statutory Auditors of the Company to hold office for five consecutive years starting

rd

from the conclusion ofthe 32nd Annual General Meeting (AGM) held on 23 September, 2023 until
the conclusion of the 37^th AGM of the Company to be held in the year 2028. The term of office of M/s
BAHEDIA & ASSOCIATES, as Statutory Auditors of the Company will conclude from the close of the
forthcoming AGM of the Company.

The Auditors'' Report is unmodified i.e. it does not contain any qualification, reservation or adverse
remark or disclaimer.

(b) SECRETARIAL AUDITORS:

The Board of Directors of the Company appointed Payal Tachak and Associates, Practicing Company
Secretary, Mumbai as Secretarial Auditors for undertaking Secretarial Audit of the Company for the
financial year 2022-23. The Secretarial Audit Report of Payal Tachak and Associates, Practicing
Company Secretary for the financial year ended 31^st March, is annexed as (Annexure - E)

The Secretarial Audit Report does contain qualification, reservation or adverse remark regarding Non¬
compliances related to FY 2022-2023.

Board would like to bring to members attention that due to resignation of Company Secretary and
change in internal as well as external Compliance team members there was gap in meeting the
Compliance requirements for FY 2022-2023. However, the same will be rectified and corrected now
onwards.

(c) INTERNAL AUDITORS:

The Board of Directors has appointed M/s. Dhiren Y Parikh & Co., Chartered Accountants as Internal
Auditors of the Company for the financial year 2022-23.

27. PARTICULARS OF EMPLOYEES AND RELATED DISCLOSURES:

The information required under Section 197 of the Companies Act, 2013 read with Rule 5(1) of the
Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, is annexed herewith.

28. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNING AND
OUTGO:

The details of conservation of energy, technology absorption, foreign exchange earnings and outgo are
attached herewith. (Annexure - D)

29. EXTRACT OF THE ANNUAL RETURN

The extract of Annual Return pursuant to Section 92(3), 134 and any other provisions applicable if any of
the Act, read with Rule 12(1) of the Companies (Management and Administration) Rules, 2014 is available
on web link http: //norrispharma.com/notice/announcements/.

30. MATERIAL CHANGES:

There have been no material changes and commitments affecting the financial position of the Company
since the close of financial year i.e. since 31st March, 2023. Further, it is hereby confirmed that there has
been no change in the nature of business of the Company.

31. DIRECTORS'' RESPONSIBILITY STATEMENT

The Directors'' Responsibility Statement referred to in clause (c) of sub-section (3) of Section 134 of the
Companies Act, 2013, shall state that—

a) in the preparation of the annual accounts, the applicable accounting standards had been followed along
with proper explanation relating to material departures;

b) the directors had selected such accounting policies and applied them consistently and made judgments
and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of
the company at the end of the financial year and of the loss of the company for that period;

c) the directors had taken proper and sufficient care for the maintenance of adequate accounting records
in accordance with the provisions of this Act for safeguarding the assets of the company and for
preventing and detecting fraud and other irregularities;

d) the directors had prepared the annual accounts on a going concern basis; and

e) the directors had laid down internal financial controls to be followed by the company and that such
internal financial controls are adequate and were operating effectively.

f) the directors had devised proper systems to ensure compliance with the provisions of all applicable
laws and that such systems were adequate and operating effectively.

32. INSURANCE:

All the properties and insurable interests of the Company including buildings, plant and machineries and
stocks have been adequately insured.

33. FRAUD REPORTING:

During the Financial Year under review, the Statutory Auditors have not reported any incident of fraud
to theBoard of Directors of the Company, pursuant to the provisions of Section 143(12) of the Companies
Act, 2013.

34. DETAILS OF APPLICATION MADE OR ANY PROCEEDING PENDING UNDER THE INSOLVENCY AND
BANKRUPTCY CODE, 2016 DURING THE YEAR ALONG WITH THEIR STATUS AS AT THE END OF THE
FINANCIAL YEAR:

During the Financial Year 2022-2023, there was no application made and proceeding initiated / pending
under the Insolvency and Bankruptcy Code, 2016, by any Financial and/or Operational Creditors against
your Company.

As on the date of this Report, there is no application or proceeding pending against your Company
under theInsolvency and Bankruptcy Code, 2016.

35. DETAILS OF DIFFERENCE BETWEEN AMOUNT OF THE VALUATION DONE AT THE TIME OF ONE TIME
SETTLEMENT AND THE VALUATION DONE WHILE TAKING LOAN FROM THE BANKS OR FINANCIAL
INSTITUTIONS ALONG WITH THE REASONS THEREOF:

During the Financial Year 2022-2023, the Company has not made any settlement with its bankers from
which ithas accepted any term loan.

36. ACKNOWLEDGEMENTS

The Board of Directors gratefully acknowledges the assistance and co-operation received from the
Bankers allother statutory and non-statutory agencies for their co-operation.

The Board of Directors also wish to place on record their gratitude and appreciation to the members for their
trustand confidence shown in the Company.

The Board of Directors would like to especially thank all the employees of the Company for their
dedication andloyalty.

Date: 18^th, November, 2023 By Order of the BoardRegistered Office: For, Norris Medicines Limited

Plot No. 801/P,

GIDC Industrial Estate,

Ankleshwar-393 002 (Gujarat) sd/-

CIN : L24230GJ1990PLC086581 Vimal D. Shah

Email: [email protected] Managing Director

DIN No. 01506655